Targeting oxidant-dependent mechanisms for the treatment of respiratory diseases and their comorbidities

Thomson, N. C. (2018) Targeting oxidant-dependent mechanisms for the treatment of respiratory diseases and their comorbidities. Current Opinion in Pharmacology, 40, pp. 1-8. (doi: 10.1016/j.coph.2017.11.013) (PMID:29223018)

154151.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.



Oxidative stress is implicated in the pathogenesis of respiratory diseases, such as COPD and its comorbidities, asthma, idiopathic pulmonary fibrosis and radiation pneumonitis. Antioxidants drugs, such as small molecule thiols, nuclear erythroid-2 related factor 2 activators and catalytic enzyme mimetics have been developed to target oxidant-dependent mechanisms. The therapeutic effects of antioxidants have been generally disappointing. A small number of antioxidants are approved for clinical use, such as the small molecule thiol N-acetyl-l-cysteine for chronic obstructive pulmonary disease, and in the United States, the superoxide dismutase mimetic AEOL 10150 for severe radiation pneumonitis. The future use of antioxidants for the treatment of chronic respiratory diseases may require a precision medicine approach to identify responsive patients.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Thomson, Professor Neil
Authors: Thomson, N. C.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Current Opinion in Pharmacology
ISSN (Online):1471-4973
Published Online:06 December 2017
Copyright Holders:Copyright © 2017 Elsevier
First Published:First published in Current Opinion in Pharmacology 40:1-8
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record